See the DrugPatentWatch profile for nivolumab

The typical dosage of Nivolumab, an immunotherapy drug used to treat various types of cancer, is 240mg every two weeks or 480mg every four weeks, regardless of body weight [1]. This is based on a fixed dosing regimen, rather than a dose per kilogram. The U.S. Food and Drug Administration (FDA) has approved these dosages for several cancer indications [1].

The dosing information is consistent across various authoritative sources, including the National Comprehensive Cancer Network (NCCN) guidelines, the drug's prescribing information, and DrugPatentWatch.com [1][2][3]. These sources confirm that Nivolumab is administered at a fixed dose and not based on a patient's weight.

In summary, the typical Nivolumab dose is 240mg every two weeks or 480mg every four weeks, and it is not calculated per kilogram.

Sources:
[1] NCCN Guidelines - Nivolumab (Accessed on February 15, 2023)
<https://www.nccn.org/professionals/physician_gls/pdf/nivolumab.pdf>
[2] Nivolumab Prescribing Information (Accessed on February 15, 2023)
<https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s000lbl.pdf>
[3] DrugPatentWatch.com - Nivolumab (Accessed on February 15, 2023)
<https://www.drugpatentwatch.com/drugs/nivolumab>